ReLIA Completes ￥100M Pre-IPO Round, Preparing Listing on the SSE Star Market

According to PEdaily.cn, RELIA Biological Engineering (Shenzhen) Co., Ltd. ("ReLIA"), a provider of equipment and reagent based on point-of-care testing (POCT) technologies, announced the completion of the Pre-IPO round of hundreds of millions yuan. This round was led by Chongyao Huisheng Healthcare Industry Fund, with participation from Feike Investment, EFUNG Investment, Enshe Family Office, and others. ReLIA has hired a number of intermediary institutions to list on the SSE Star Market within the year.

Since its foundation in 2001, ReLIA has been at the forefront of research in point of care testing technologies, with its primary research and development center located in Silicon Valley, California. Currently, it holds its Asian Pacific headquarters at the Shekou Free Trade Zone, Shenzhen, as well as large scale production and R&D centers in Shenzhen and Jiangsu. These centers have passed both the CFDA and ISO-13485 audit certification.

Currently, ReLIA focuses on two categories of rapid detection systems, the multi-functional immunoassay system, and immunofluorescence detection system. Both of these systems cover the detection of biomarkers for cardiovascular, acute kidney injury, and inflammatory-related conditions. 

Based on the advanced technology platform, ReLIA rapidly launched a kind of rapid diagnostic reagent (based on immunization method) during this coronavirus outbreak. The company's POCT devices and reagents have been widely recognized by first-line medical staff in Wuhan Huoshenshan Hospital and other important anti-epidemic fronts due to their advantages of speed, accuracy, portability and avoiding cross-infection.

Founded in February 2011, Feike Investment provides industrial investment, real estate investment, investment management, investment consulting and other services for clients.

EFUNG Investment is one of China's earliest institutions investing in professional biomedical industries. Over a decade of years, EFUNG Investment has been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices.